Corcept Therapeutics Incorporated (NASDAQ:CORT) shares fell to a low of $21.35 before closing at $21.67. Intraday shares traded counted 0.41 million, which was 25.37% higher than its 30-day average trading volume of 543.24K. CORT’s previous close was $21.45 while the outstanding shares total 116.82M. The firm has a beta of 0.73, a 12-month trailing P/E ratio of 27.43. The stock’s Relative Strength Index (RSI) is 46.78, with weekly volatility at 2.33% and ATR at 0.67. The CORT stock’s 52-week price range has touched low of $12.20 and a $31.18 high. The stock traded higher over the last trading session, gaining 1.03% on 05/27/21.
Investors have identified the Biotechnology company Corcept Therapeutics Incorporated as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.53 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Corcept Therapeutics Incorporated (CORT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 409.62 million total, with 40.6 million as their total liabilities.
CORT were able to record 25.3 million as free cash flow during the 08/03/2021 quarter of the year, this saw their quarterly net cash flow reduce by -23.81 million. In cash movements, the company had a total of 25.42 million as operating cash flow.
Potential earnings growth for Corcept Therapeutics Incorporated (CORT)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/03/2021 quarter of the year, Corcept Therapeutics Incorporated recorded a total of 79.44 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -17.38% coming in sequential stages and their sales for the 08/03/2021 quarter reducing by -7.93%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.27 million trying to sell their products during the last quarter, with the result yielding a gross income of 78.17 million. This allows shareholders to hold on to 116.82M with the recently reported earning now reading 0.20 cents per share. This is a figure that compared to analyst’s prediction for their 08/03/2021 (0.18 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.98 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CORT sounds very interesting.
Is the stock of CORT attractive?
In related news, Chief Financial Officer, Robb Gary Charles sold 10,000 shares of the company’s stock in a transaction that recorded on Apr 23. The sale was performed at an average price of 24.02, for a total value of 240,219. As the sale deal closes, the Director, Swisher Daniel N JR now sold 7,500 shares of the company’s stock, valued at 181,036. Also, Chief Accounting Officer, Lyon Joseph Douglas sold 25,000 shares of the company’s stock in a deal that was recorded on Apr 01. The shares were price at an average price of 23.88 per share, with a total market value of 597,030. Following this completion of acquisition, the Chief Accounting Officer, Lyon Joseph Douglas now holds 25,000 shares of the company’s stock, valued at 630,320. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.50%.
2 out of 4 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Corcept Therapeutics Incorporated. 0 analysts has assigned a Sell rating on the CORT stock. The 12-month mean consensus price target for the company’s shares has been set at $26.50.